The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
TOPARP-B: A phase II randomized trial of the poly(ADP)-ribose polymerase (PARP) inhibitor olaparib for metastatic castration resistant prostate cancers (mCRPC) with DNA damage repair (DDR) alterations.
Joaquin Mateo
Consulting or Advisory Role - AstraZeneca; Janssen; Roche (Inst)
Speakers' Bureau - Astellas Pharma; AstraZeneca; Sanofi
Travel, Accommodations, Expenses - AstraZeneca; Ipsen; Sanofi
Other Relationship - BeiGene
Nuria Porta
No Relationships to Disclose
Ursula Brigid McGovern
Travel, Accommodations, Expenses - Janssen Oncology
Tony Elliott
Research Funding - Per patient clinical trial commercial income from multiple pharmaceutical companies; Per patient clinical trial commercial income from multiple pharmaceutical companies (Inst)
Travel, Accommodations, Expenses - Janssen
Robert J Jones
Honoraria - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; EUSA Pharma; Ipsen; Janssen; MSD Oncology; Novartis; Pfizer; Pharmacyclics; Roche/Genentech; Sanofi; Seattle Genetics
Consulting or Advisory Role - Clovis Oncology
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Clovis Oncology (Inst); Exelixis (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; Bayer; Ipsen; Janssen; MSD
Isabel Syndikus
Travel, Accommodations, Expenses - Bayer
Christy Ralph
Honoraria - Bristol-Myers Squibb; Novartis; Pfizer
Consulting or Advisory Role - Bristol-Myers Squibb
Research Funding - Eisai (Inst); Merck (Inst); Roche (Inst); Viralytics (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; Bristol-Myers Squibb; GlaxoSmithKline; Ipsen; Janssen; Roche
Suneil Jain
Consulting or Advisory Role - Almac Diagnostics; Astellas Pharma; Bayer; Janssen-Cilag; Movember Foundation
Speakers' Bureau - Augmenix; Genzyme; Janssen-Cilag
Travel, Accommodations, Expenses - Astellas Pharma; Janssen-Cilag
Mohini Anna Varughese
Speakers' Bureau - Genomic Health; Roche
Omi Parikh
Honoraria - Bristol-Myers Squibb; Ipsen; Janssen
Consulting or Advisory Role - Bristol-Myers Squibb
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Janssen
Simon J. Crabb
Honoraria - Astellas Pharma; Bayer; Janssen-Cilag; MSD; Roche
Consulting or Advisory Role - AstraZeneca; Bayer; BeiGene; Clovis Oncology; Janssen-Cilag; MSD; Roche
Research Funding - Astex Pharmaceuticals; AstraZeneca; Clovis Oncology; Plexxikon
Travel, Accommodations, Expenses - Bayer; Bristol-Myers Squibb; Janssen-Cilag; Roche
Susana Miranda
No Relationships to Disclose
George Seed
No Relationships to Disclose
Claudia Bertan
No Relationships to Disclose
Aude Espinasse
Research Funding - AstraZeneca (Inst)
Peter Chatfield
Research Funding - AstraZeneca (Inst); Bayer (Inst)
Diletta Bianchini
Honoraria - Janssen
Travel, Accommodations, Expenses - Janssen
Emma Hall
Research Funding - Accuray (Inst); Alliance Pharma (Inst); AstraZeneca (Inst); Aventis Pharma (Inst); Bayer (Inst); Kyowa Hakko Kirin (Inst); Merck Sharp & Dome (Inst)
Suzanne Carreira
No Relationships to Disclose
Johann S. De Bono
Honoraria - Astellas Pharma; AstraZeneca; BioExcel; Daiichi Sankyo; Genentech/Roche; Janssen Oncology; Menarini Silicon Biosystems; Pfizer; Sanofi; Sierra Oncology
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; BioXCel therapeutics; Boehringer Ingelheim; Celgene; Daiichi Sankyo; Eisai; Genentech/Roche; Genmab; GlaxoSmithKline; Janssen Oncology; Menarini Silicon Biosystems; Merck Serono; Merck Sharp & Dohme; Orion; Pfizer; Sanofi; Sierra Oncology; Taiho Pharmaceutical
Research Funding - Astex Pharmaceuticals (Inst); AstraZeneca (Inst); Bayer (Inst); Celgene (Inst); CellCentric (Inst); Daiichi Sankyo (Inst); Genentech (Inst); GlaxoSmithKline (Inst); MedImmune (Inst); Medivation (Inst); Merck Serono (Inst); Merck Sharp & Dohme (Inst); Orion (Inst); Sanofi (Inst); Sierra Oncology (Inst); Taiho Pharmaceutical (Inst)
Patents, Royalties, Other Intellectual Property - Abiraterone Rewards to Inventors (Inst); CHK1 inhibitor (Inst); PARP inhibitors and DNA repair defects (Inst); Targeting of IL23 in prostate cancer (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; AstraZeneca; Genmab; GlaxoSmithKline; Orion; Qiagen; Sanofi; Taiho Pharmaceutical; Vertex